Generic drug reviews
Executive Summary
FDA plans to review 90% of ANDAs within six months as part of its fiscal year 2004 Performance Plan, a 10% increase over the agency's 2003 goal. "We plan to improve the review of ANDAs without sacrificing product quality to allow the agency to reach its goal of reviewing 80% of ANDAs in FY 2003 and 90% in FY 2004 within six months after submission," the agency's 1website states. The plan also includes a goal to review 55% of 630 high-risk manufacturers in fiscal year 2004...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.